Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy.

PURPOSE We report a prospective study examining the ability of preoperative nested reverse transcriptase polymerase chain reaction (RT-PCR) for prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSM) to predict pathologic stage and biochemical recurrence in patients with clinically localized prostate cancer treated with radical prostatectomy. PATIENTS AND METHODS One hundred forty-one patients were entered onto the study. Preoperative evaluation included clinical T stage, serum PSA, biopsy Gleason score, and serum RT-PCR for PSA/PSM. Univariate and multivariate logistic regression models, Kaplan-Meier estimates, and Cox proportional hazards modeling were used to identify predictors of pathologic stage and biochemical failure. RESULTS Seventy-three patients (51.8%) were RT-PCR positive for PSA, PSM, or both. In the multivariate logistic regression model, only initial PSA was an independent predictor of pathologic stage as defined by organ-confined disease (odds ratio [OR], 1.06; 95% confidence interval [CI], 1.00 to 1.13; P =.026) or organ-/specimen-confined disease (OR, 1.09; 95% CI, 1.02 to 1.16; P =.009). Overall Kaplan-Meier biochemical relapse-free survival (bRFS) was 85% at 59 months. Multivariate analysis of predictors for bRFS with the Cox proportional hazards model indicated that only initial PSA (OR, 1.05; 95% CI, 1.02 to 1.09; P =.004) and biopsy Gleason score (OR, 3.57; 95% CI, 1.37 to 9.58; P =.009) were independent predictors of biochemical failure. RT-PCR status did not predict pathologic stage or biochemical failure. Repeat analysis excluding 27 patients who received preoperative androgen-deprivation therapy did not change the results. CONCLUSION Combined nested RT-PCR for PSA and PSM is not an independent predictor of pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy. This assay has no clinical utility in this patient population.

[1]  P. Kantoff,et al.  Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  H. Levin,et al.  No difference in biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients. , 2000, Urology.

[3]  N. Brousse,et al.  Detection of circulating prostate derived cells in patients with prostate adenocarcinoma is an independent risk factor for tumor recurrence. , 2000, The Journal of urology.

[4]  G. Murphy,et al.  Detection of extraprostatic prostate cells utilizing reverse transcription-polymerase chain reaction. , 2000, Seminars in surgical oncology.

[5]  H. Levin,et al.  Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  D. Chopin,et al.  Blood‐based reverse transcriptase polymerase chain reaction assays for prostatic specific antigen: Long term follow‐up confirms the potential utility of this assay in identifying patients more likely to have biochemical recurrence (rising PSA) following radical prostatectomy , 1999, International journal of cancer.

[7]  J. Moul,et al.  Blinded evaluation of reverse transcriptase-polymerase chain reaction prostate-specific antigen peripheral blood assay for molecular staging of prostate cancer. , 1999, Urology.

[8]  R. Figlin,et al.  Quantitative Polymerase Chain Reaction Does not Improve Preoperative Prostate Cancer Staging: A Clinicopathological Molecular Analysis of 121 Patients , 1998 .

[9]  W. Ellis,et al.  The value of a reverse transcriptase polymerase chain reaction assay in preoperative staging and followup of patients with prostate cancer. , 1998, Journal of Urology.

[10]  Manjula.,et al.  Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: correlation with pathological stage. , 1998, Cancer Research.

[11]  J. Chmiel,et al.  Prostate specific antigen reverse transcriptase-polymerase chain reaction assay in preoperative staging of prostate cancer. , 1997, The Journal of urology.

[12]  F. V. Lente,et al.  Combined nested reverse transcription-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in detecting circulating prostatic cells. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  M. Rubin,et al.  The role of the reverse-transcriptase polymerase chain reaction assay for prostate-specific antigen in the selection of patients for radical prostatectomy. , 1996, The Urologic clinics of North America.

[14]  M. Benson,et al.  The use of RT-PCR for prostate-specific antigen assay to predict potential surgical failures before radical prostatectomy: molecular staging of prostate cancer. , 1996, British journal of urology.

[15]  B. Lacour,et al.  Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma by using nested reverse transcription polymerase chain reaction assay based on prostate-specific membrane antigen. , 1995, Clinical chemistry.

[16]  M. Benson,et al.  Molecular Stating of Prostate Cancer. II. A Comparison of the Application of an Enhanced Reverse Transcriptase Polymerase Chain Reaction Assay for Prostate Specific Antigen Versus Prostate Specific Membrane Antigen , 1995 .

[17]  A. Deblasio,et al.  Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. , 1994, Cancer research.

[18]  S. Schwartz,et al.  CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. , 1994, Cancer research.

[19]  M. Benson,et al.  Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. , 1994, Urology.